The United States Patent and Trademark Office (USPTO) has issued patent grant US12583868B2 to Galderma Holding SA, detailing novel compounds identified by formula (I) and methods for their synthesis and therapeutic use. The patent, classified under CPC C07D 498/14, focuses on JAK inhibitors and their application in treating diseases, conditions, and disorders. The filing date for this application was March 13, 2023, with 12 claims.

This patent grant represents a new intellectual property right for the assignee, Galderma Holding SA, concerning specific chemical compounds and their medicinal applications. While patent grants do not impose direct regulatory obligations on other entities, they establish exclusive rights that can impact market entry and competition for pharmaceutical companies and drug manufacturers. Companies operating in this space should be aware of this granted patent to ensure their research, development, and commercial activities do not infringe upon the patent holder's exclusive rights.